A limitation of successful stem cell gene transfer to hematopoietic stem cells is low transduction efficiency. 
H ematopoietic stem cell gene transfer as a method to treat genetic diseases and patients with cancer has been receiving increasing attention. However, long -term persistence of only a small number of transduced hematopoietic progenitor cells was demonstrated in gene marking studies using the neomycin phosphotransferase gene ( Neo ) 1,2 and in human clinical trials studies using the multidrug resistance gene ( mdr1 ). 3, 4 To improve retroviral stem cell transduction, many different strategies aimed at increasing viral attachment and stem cell proliferation without differentiation have been explored. 5 Improved transduction of CD34 + progenitors was recently demonstrated ( 50-80% ) with the use of fibronectin fragments (retronectin ) or stromal cell layercoated plates, which enhance co -localization of virus. 6 More recently, improved transduction of human CD34 + cells was reported in a clinical trial that employed retronectin to modify cells with the mdr1 gene. 7 Application of the cytokines TPO, FLT3 and c -kit ligand improves transduction of primitive hematopoietic progenitor cells by promoting cell cycle and stem cell self -renewal. 8 The use of drug resistance genes as selectable markers may provide a means for allowing persistence and even enrichment of transduced stem cells in vivo. Our group and others have developed drug resistance genes with improved ability to protect host cells against chemotherapeutic toxicity. Various genes that confer drug resistance to hematopoietic cells, e.g., mutant human dihydrofolate reductase ( DHFR ) genes, 9 -12 human DNA alkyltransferase genes, 13, 14 and the mdr1 gene (p -glycoprotein ), 3, 4, 7, 15 have been generated. Our group and others have previously tested various models to show hematopoietic cell selection by methotrexate ( MTX ). Flasshove et al 11 have demonstrated selection for a pre -CFC population of human CD34
+ -enriched cells transduced with mutant DHFR in liquid culture system. Allay et al 12 used in vivo competitive repopulation assay in a mouse model to show that mouse bone marrow cells transduced with mutant DHFR were selectively enriched in vivo by simultaneous administration of trimetrexate (TMTX ) treatment of thymidine transport inhibitor. However, to our knowledge, there have been no reports demonstrating MTX selection of primitive human hematopoietic cells.
In this study, we constructed a retrovirus containing a human mutated DHFR (Phe22 /Ser31; F /S ) cDNA 16 fused to an enhanced green fluorescent protein (EGFP ) cDNA. The ''humanized'' EGFP gene from the jellyfish Aequorea victoria has been widely used as a tool to trace retrovirally transduced hematopoietic progenitors. It allows for rapid identification of transduced cells by fluorescence microscopy and flow cytometry. 17, 18 Transduced human hematopoietic progenitors, including week 5 cobblestone area forming cell (CAFC ) and LTC -IC, were directly visualized in long -term culture ( LTC ) by fluorescence microscopy. Week 5 CAFC and LTC -IC are in vitro surrogates for stem cells. 19, 20 The CAFC assay and the LTC -IC assay allow for frequency analysis of primitive cells capable of long -term repopulation in vitro. 21 Based on previous studies, this assay may be used to assess the effect of manipulation of human hematopoietic progenitor cell populations by gene transfer methods. 22 Recent studies showed that retroviral gene transduction can be assessed in both CAFC and in the NOD / SCID mice transplantation model using purified CD34 + and CD34 + CD38 À umbilical cord blood (UCB ) cells. 18 The main goal of this study was to test the efficacy of MTX selection for DHFR -transduced human CAFC. 23 We used the mutated DHFR (F /S ) and EGFP fusion (F / S-EGFP ) retroviral constructs in a long term stromal coculture system, thus ensuring that both genes were equally expressed. MTX exposure was found to select for EGFP + CAFC and secondary CFU -GM ( LTC -IC ) measured at 5 weeks. These investigations have implications for the use of gene transfer of DHFR to limit MTX -induced myelotoxicity in cancer patients.
Materials and methods
Human peripheral blood progenitor cells ( PBPCs ) and CD34 + cell selection
All leukapheresis products used for PBPC isolation were specimens from deceased cancer patients. Based on the IRB -approved consent and the family member's agreement, we used the specimens that were designated to be discarded. Following PBPC mobilization with chemotherapies and G -CSF, leukapheresis specimens were harvested, cryopreserved, and stored in the Stem Cell Laboratory at Memorial Sloan -Kettering Cancer Center. Mononuclear cells were isolated from thawed specimens by Ficoll-Paque ( Pharmacia, Piscataway, NJ ) density gradient centrifugation. CD34 + cell selection was performed using the StemSep system per manufacturer's instructions ( StemCell Technologies, Vancouver, Canada ). CD34
+ -selected cells were incubated with R -phycoerythrin ( PE )-conjugated antibodies against human CD34 (C34 -PE; Becton Dickinson, San Jose, CA ) for 30 minutes on ice in PBS supplemented with 2% fetal bovine serum (FBS ). After incubation, the cells were washed twice, resuspended in PBS, and the percentage of CD34 + cells was determined using FACS ( FACScalibar; Becton Dickinson).
Generation of a fusion protein F / S -EGFP
The coding sequence of human mutated DHFR ( F /S ), fused to a sequence encoding a consensus thrombin cleavage site, was generated in the bacterial expression vector pkT7 ( Clontech Laboratories, Palo Alto, CA ) to yield a plasmid pkT7 F /S. A 720 -bp fragment of EGFP was generated by polymerase chain reaction (PCR ) amplification of pEGFP -N1 (Clontech Laboratories ) using the following primers: EGFPBHI: 5 0 -GTTCCGCGTGGATCCCCGGGAATTGT-GAGCAAGGGCGAGGAGCTG; EGFPSTOPIII: 5 0 -ATC-ATCATCAAGCTTTTACTTGTACAGCTCGTCCATGCC-GAG. The forward primer EGFPBHI contained BamHI and SmaI restriction sites and a reverse primer EGFPSTOPIII contained XhoI and HindIII restriction sites.
The PCR -amplified fragment and the pKT7 -F /S vector were digested with BamHI /HindIII. The purified EGFP PCR product was ligated into the pKT7 -F /S vector backbone to yield pKT7 -F /S -EGFP. This sequence was confirmed by restriction digestion and DNA sequencing. Escherichia coli BL21 cells were transformed with pKT7 -F /S -EGFP, grown to a density of OD 0.6 -0.8, and induced with 1 mM isopropyl -D -thiogalactopyranoside (IPTG ) for 5 hours. The transformed cells were harvested and resuspended in buffer ( 10 mM Tris, 0.1 mM EDTA ), sonicated (5 seconds every 15 seconds Â4 on ice ), followed by incubation at 958C for 5 minutes. The crude lysate was obtained after centrifugation at 15,000 rpm for 20 minutes. Next, the supernatant and the whole lysate were electrophoresed, side by side, on a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS -PAGE ) minigel ( 12% ) to confirm the correct molecular weight of the fusion protein product. Noninduced lysates served as controls. The detailed enzyme kinetics of F /S -EGFP fusion protein and other F /S fusions constructed in our laboratory is the subject of another manuscript in preparation. Quantitation of GFP fluorescence of F /S -EGFP -transfected cells is discussed in the Generation of Amphotropic and Ecotropic Producer Cell Lines section.
Construction of retroviral vectors SFG -F / S -EGFP and SFG -EGFP -IRES-Neo
The MMLV-based SFG retroviral vector, SFG -F /S -EGFP, contained the fusion gene F /S -EGFP cDNA (vide supra ) ( Fig 1 ) . The vector construct SFG -EGFP -IRES -Neo was used as a control. The Neo gene was included in the control vector to facilitate selection of producer cell lines. The SFG -F /S -EGFP (Fig 1A ) was constructed from pkT7 -F / S -EGFP and cloned into an SFG -based retroviral vector backbone. 16 The SFG -EGFP -IRES -Neo ( Fig 1B ) was generated by subcloning the EGFP fragment obtained from the pEGFP -N1 vector (Clontech Laboratories ) into the NcoI/NotI site of the SFG backbone. The resultant plasmid, SFG -EGFP, was then digested with NotI/XhoI restriction sites. An internal ribosomal entry site ( IRES )-Neo fragment, excised from pBlue IRES -Neo plasmid (subcloned in our laboratory from SFG -F /S -IRES -Neo vector ), was ligated with SFG -EGFP to yield the SFG -EGFP -IRESNeo vector.
Generation of amphotropic and ecotropic producer cell lines line, 24, 25 were generated by co -transfection of SFG -F / S-EGFP and pSV2Neo at a molar ratio of 10:1 26 using DOTAP reagent ( Boehringer-Mannheim, Indianapolis, IN). GP -E86 SFG -EGFP -IRES -Neo and GP -AM12 SFG -EGFP-IRES -Neo were also generated by transfection using DOTAP reagent. Transfected cells were selected with G418 ( 750 g /mL ) for 14 days. The selection of the best producer cell line was carried out by two -step procedure. First, each producer cell clone was analyzed by flow cytometry according to the intensity of GFP. Both SFG -F/ S -EGFP-and SFG -EGFP -IRES -Neo -transfected producer cell clones showed 10 3 -10 4 fluorescent intensity compared to that of control cells, which were in the range of 10 0 -10 2 . The degree of GFP intensity in fusion construct was comparable to that of nonfusion construct. The percentage of GFP + cells detected by FACS analysis and fluorescent microscopic analysis was identical. The second step was to submit preselected producer clones for the viral titer estimated by infecting NIH3T3 cells and then selecting with MTX ( 150 nM ) or G418 (750 g /mL ) for 14 days as described previously. 27 We chose the highest titer clone, GP -AM12 SFG -F /S -EGFP, for the following procedure to further increase the titer. We infected the amphotropic producer cell line ( GP -AM12 SFG -F /S -EGFP ) with the supernatant from the ecotropic producer cell line ( GP -E86 SFG -F /S -EGFP) 10 times over 10 days in the presence of fresh 8 g /mL polybrene. The final viral titer of the AM12 SFG -F /S -EGFP was 1-2Â10 7 colony -forming units / mL ( cfu / mL ) showing approximately 1 log improvement of the titer. The titer of GP -AM12 SFG -EGFP -IRES -Neo was 5Â10 5 cfu / mL. These producer cell lines were free of replication -competent retrovirus as demonstrated by failure of MTX or G418 resistance to be transferred from virally transduced NIH3T3 cells to nontransduced NIH3T3 cells as described previously. 17 The selected producer cell lines were confirmed by FACS and fluorescent microscopy for GFP expression.
Retroviral transduction of NIH3T3 cells
NIH3T3 cells were exposed to virus -containing supernatant for 6 hours in the presence of 8 g /mL polybrene at an MOI of 5. The following day, the medium was changed to either G418 ( 750 g/mL ) or TMTX (20 nM ) for 10 days, for the vectors containing the Neo gene or F /S gene, respectively. This concentration of TMTX is 100% lethal to nontransduced NIH3T3 cells, but is not inhibitory to F /S -DHFR infected cells. 28 PCR analysis of genomic DNA from NIH3T3 cells Genomic DNA from NIH3T3 cells was isolated as described previously. 27 Two hundred nanograms of genomic DNA was used for each PCR reaction. EGFP cDNA was amplified using the following primers: forward EGFP1 (5 0 -GCCA-CAAGTTCAGCGTGTCC -3 0 ) and reverse EGFP2 (5 0 - Cancer Gene Therapy DHFR-EGFP fusion gene and MTX selection N Takebe et al AGCTCGATGCGGTTCACCAG -3 0 ) primers. 29 The resultant PCR product was approximately 300 bp.
Protection of NIH3T3 cells infected with retroviral vectors containing a fusion gene of human mutated DHFR ( F / S ) and EGFP from MTX toxicity
MTX was prepared from a stock solution ( 10 À 2 M) stored at À 708C. MTX cytotoxicity was measured by a colorimetric assay using XTT (sodium 3 0 -{1 -[ (phenylamino)-carbonyl]-3,4-tetrazoliu} -bis( 4 -methyoxy-6-nitro) benzene -sulfonic acid hydrate ) as described previously.
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NIH3T3 cells that were infected with viral supernatant and selected as described ( vide supra ) were plated in 96-well plates (400 cells per well ). The following day, infected cells were exposed to varying doses of MTX, using media containing dialyzed FBS. After 5 days of exposure to MTX, 50 L of 1 mg /mL XTT and 0.025 mM phenazine methosulfate ( PMS ) were added. The absorbance of the supernatant was measured at 450 and 630 nm with wells without drug (with cells ) as 100% and wells without cells as 0%. To assess the GFP sensitivity in transduced cells by both fusion vector and control vector, we analyzed an aliquot of the same cells used for the cytotoxicity assay by FACS analysis and fluorescence microscopy.
Western blotting
Protein lysates were prepared from cells transduced by SFG -F /S -EGFP, SFG -EGFP -IRES -Neo, SFG -F/S-IRES-Neo, 16 mock -transduced cells, and the DHFR À / À DG44 CHO cell line ( used as a negative control ). Cells were lysed in a buffer containing proteinase inhibitors as previously described. 31 After a 20-minute incubation on ice and centrifugation at 15,000Âg for 20 minutes, the supernatant was recovered. Protein concentration was determined by the BioRad (Hercules, CA) reagent per manufacturer's instructions using BSA as a standard. Lysate, containing 75 g of protein, was used for electrophoresis on 12.5% SDS -PAGE. After transfer to a nitrocellulose membrane, the membrane was incubated for 2 hours with antihuman DHFR antibody, a rabbit polyclonal antiserum raised against recombinantly expressed human DHFR protein. The membrane was then incubated in a goat antirabbit secondary antibody ( Santa Cruz Biotech, Santa Cruz, CA ). The protein bands were visualized on X -ray film using the enhanced chemiluminescence reagent from Amersham (Arlington Heights, IL). After autoradiography, the membrane was stripped and incubated with an anti -GFP antibody (Clontech Laboratories ), followed by antimouse secondary antibody (Santa Cruz Biotech ). The bands were visualized as described above.
Retroviral transduction of PB CD34 + cells
Supernatants containing recombinant retrovirus were generated from the producer cells described above. The producer cell line was expanded and aliquots were frozen in multiple tubes until use. The titer of the producers was measured immediately after the first round of cell culture passage and then again after the cells were expanded in culture. Viral titer was again measured after expanding and splitting the cells three times. The titer was found to be consistent throughout this procedure. Because our transduction procedure involved multiple rounds of infection in fresh supernatant, we also titered the supernatant used in the first and last round of infections. Infections were performed on Retronectin 1 ( Takara Shuzo, Otsu, Japan ) coated dishes, as per manufacturer's instructions. Following overnight prestimulation in media containing human recombinant interleukin -6 ( IL -6; 20 ng/ mL; R&D Systems, Minneapolis, MN ), thrombopoietin ( TPO; 100 ng /mL; R&D Systems ), stem cell factor (SCF; 20 ng/ mL; Immunex, Seattle, WA ), Flt -3 ligand ( FLT3; 100 ng/mL; Imclone, New York, NY ), and human granulocyte -macrophage colony -stimulating factor ( GM -CSF; 100 ng/ mL; Immunex ), the CD34 + -enriched population was transduced with either AM12 SFG -F /S -EGFP, AM12 SFG -EGFP -IRES -Neo, or mock AM12 viral supernatants. Retroviral infection was performed twice a day for 4 days at an MOI of 20 for SFG -F /S -EGFP and at an MOI of 1 for SFG -EGFP -IRES -Neo. Each infection was performed by resuspending the cells in fresh virus supplemented with cytokines. On day 5, the cells were harvested and FACS analysis, human granulocyte -macrophage CFU (CFU -GM ), erythroid burst -forming units ( BFU -E ) assays, and LTC -IC assays performed.
Flow cytometry
Cell samples were analyzed using a FACScalibar ( Becton Dickinson ). Immunophenotyping of EGFP -transduced cells was performed by staining with PE -conjugated CD34 (vide supra ).
In vitro colony assay
Transduced progenitors were assayed for CFU -GM and BFU -E colony formation in methylcellulose as previously described. 11 The cells were plated with increasing doses of MTX mixed in methylcellulose culture medium with BSA ( StemCell Technologies ) and additional human recombinant erythropoietin (EPO; 3 U /mL ) (Amgen, Thousand Oaks, CA ). Cells were plated in triplicate. The number of colonies was determined after 14 -16 days of culture in a humidified atmosphere of 5% CO 2 at 378C. EGFP containing colonies were scored using fluorescence microscopy.
LTC and CAFC assay
The MS-5 murine marrow stromal cell line (Kirin Pharmaceuticals, Tokyo, Japan ) was used to support hematopoietic progenitors during the LTC. 34 MS -5 cells were seeded in T25 flasks and grown to confluence prior to the initiation of LTC. An equal number of mocktransduced or vector-transduced CD34 + enriched cells were seeded onto the stroma (0.8 -1.125Â10 5 cells per flask for each experiment ). Cells were maintained in modified LTC media containing thymidine phosphorylasetreated FBS. 32 Thymidine phosphorylase-treated FBS was used in LTC media to decrease background colonies as the cytotoxicity of antifolates was attenuated by the thymidine salvage. FBS contains a high level of this metabolite. 
MTX (5Â10
À 8 M) and without MTX. Each culture was run in triplicate. Each week, the LTC was demidepopulated and fresh LTC medium with or without MTX was added (5Â10 À 8 M). Demi -depopulation involves removal of half the total culture media and suspension cells and then replenishment with the same volume of fresh media, such that the total culture volume and concentration of MTX remain constant throughout the 5 -week period. This MTX concentration was not cytotoxic to MS-5 stromal layers, but was 100% lethal to nontransduced peripheral blood CD34 + -enriched cells by CFU -GM assay ( unpublished data ). Cell counts and FACS analysis were performed each week. All LTCs were carried out for 5 weeks. CFU -GM assays were performed at weeks 0 and 5. Phase dark hematopoietic clones of at least eight cells (i.e., CAFCs) beneath the stromal layer was determined at week 5 using an inverted microscope. Green fluorescent cobblestone areas were screened in the same way, but with an UV light excitation source (Eclipse TE200; Nikon, Melville, NY ). LTC -IC values were calculated from the colony numbers detected in the secondary CFU -GM assay at week 5.
EGFP cDNA detection in CFU -GM colonies by PCR After 14 days of culture in methylcellulose, CFU -GM colonies were analyzed by fluorescence microscopy as well as by PCR. Individual large colonies were harvested by a pipette and transferred into 0.5 -mL Eppendorf tubes, suspended in PBS, and washed twice. The pellet was resuspended in Higuchi's buffer 33 with proteinase K, incubated at 558C for 3 hours, followed by inactivation of proteinase K (958C for 10 minutes ). For PCR, -actin primers were used to test the quality of genomic DNA, and EGFP primers (forward: EGFP1 and reverse: EGFP2, sequence described as above ) were used for transgene 
Results

Retroviral vector expression in NIH3T3 cells
Retroviral vectors shown in Figure 1 were first tested by transduction of NIH3T3 cells. NIH3T3 cells were used as target cells for testing vector expression because this cell line is very sensitive to MTX, which enabled accurate testing of MTX resistance. Also, the antibody to human DHFR preferentially recognizes the human and not the mouse enzyme. NIH3T3 cells were transduced with amphotropic retrovirus encoding the human F /S -EGFP fusion gene, or a retrovirus encoding EGFP and Neo as a control. After appropriate drug selection using G418 or MTX (see Materials and Methods ), both control vector and SFG -F / S -EGFP vector -transduced cells were nearly 100% positive for EGFP as determined by both either fluorescence microscopy and FACS analysis. The intensity of EGFP fluorescence in SFG -F /S -EGFP -transduced cells was also comparable to fluorescence of SFG -EGFP -IRES -Neotransduced cells.
Proviral DNA was detected in transduced NIH3T3 cells by PCR amplification of a 310 -bp EGFP fragment ( Fig 2 ) . As expected, no EGFP DNA was detected in mock -transduced NIH3T3 cells. In order to demonstrate protein expression, cell lysates from vector-transduced and mock -transduced clones were analyzed by Western blot using antibodies to human DHFR and EGFP (Fig 3 ) . Pure DHFR ( 50 ng) 
MTX cytotoxicity assays in NIH3T3 cells
To test whether increased expression of F /S -EGFP fusion protein led to MTX resistance, SFG -F /S -EGFP and mocktransduced NIH3T3 cells were exposed to increasing doses of MTX. SFG -F /S -EGFP -transduced cells were selected by treatment with 20 nM TMTX for 10 days. The IC 50 for MTX cytotoxicity toward SFG -F /S -EGFP -transduced cells was determined by the XTT assay to be 5.2 ± 0.6 M ( results from three separate experiments were 4.5, 6, and 5 M ), a 250 -fold increase over mock -transduced control cells ( Fig 4) .
Transduction efficiency in PBSC CD34 + -enriched cells with the F / S -EGFP vector
CD34
+ -enriched cells were transduced with either mock, SFG -EGFP-IRES -Neo, or SFG -F /S -EGFP viral supernatant for 4 days in fibronectin-coated dishes with an MOI of 1 for SFG -EGFP -IRES -Neo and an MOI of 20 for SFG -F / S-EGFP construct. Fresh media and cytokines were added twice a day during the period of transduction ( see Materials and Methods). The experiment was repeated four times using CD34 + -enriched progenitor cells isolated from mobilized peripheral blood (mPB ). The mPB samples were + -enriched cells separated from leukapheresis material from different patients ( see Materials and methods ). After the transduction procedure, the cells were analyzed for CD34 and GFP expression by FACS analysis before initiating LTC and colony assays.
yFusion stands for the vector SFG -EGFP -IRES -Neo and SFG -F / S -EGFP, respectively. NP stands for ''not performed''. Experiments 1 to 4 utilized human CD34 + -enriched cells separated from leukapheresis material from different patients ( see Materials and Methods ). After the transduction procedure, the cells were analyzed for CD34 and GFP expression by FACS analysis before initiating LTC and colony assays. Table 1 . Transduction with SFG -F /S -EGFP, as determined by FACS analysis for GFP expression, is also shown in Table 1 
FACS analysis of suspension cell population
Suspension cells from SFG -F /S -EGFP LTCs were analyzed for EGFP expression by FACS analysis ( Fig 6) . Cells analyzed for GFP expression were harvested at the time of weekly demi -depopulation. In each experiment, the per- 
Transduction efficiency and MTX selection of CAFC subsets
The ability of transduced cells to form cobblestone areas was evaluated at week 5 of LTC ( Fig 7) . The absolute numbers of CAFC derived from mock, control, and fusion protein vector -transduced cells without MTX treatment were comparable within each experiment. The percentage of GFP + CAFC in the SFG -EGFP -IRES -Neo cultures was lower than that of the fusion vector -transduced cultures. This finding reflected the lower initial transduction efficiency of the control vector (5 -12% ) compared with the fusion vector (16 -78% ) . The absolute number of CAFC All experiments showed high %GFP ( 98%, 97%, 96%, and 97% ) as a consequence of MTX selection, but the nonselection group did not show a significant increment of %GFP ( 61%, 20%, 17% , and 53% ). Table 2 ). The percentage of GFP + CAFC at week 5 without MTX in experiments 1, 2, 3, and 4 was 53%, 28%, 24%, and 81%, whereas in the presence of MTX, the percentage was 100%, 96%, 100%, and 100%, respectively.
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MTX resistance conferred by the SFG -F / S -EGFP vector measured by CFU -GM and BFU -E assays
Aliquots of cells were assayed for CFU -GM and BFU -E at weeks 0 and 5 of LTC. Clonogenic assays were performed with and without MTX. The mock or SFG -EGFP -IRESNeo vector -transduced groups did not show any surviving colonies at the concentration of 5Â10 À 8 M MTX at week 0 or 5 in all experiments (Table 3 ). In contrast, week 0 CFU -GM and BFU -E that were transduced with SFG -F /S -EGFP demonstrated resistance to MTX, with 6-80% survival at M MTX. Similarly, CFU -GM colonies generated by week 6 suspension cells treated with 10 À 6 M MTX were 100% GFP + .
EGFP detection in CFU -GM colonies by PCR
PCR analysis was performed to detect proviral sequences in weeks 0 and 5 CFU -GM ( Fig 8 ) . DNA from seven colonies at week 0, generated by SFG -F /S -EGFP and mocktransduced cells and grown in the absence of MTX, was analyzed for EGFP cDNA. While all mock -transduced colonies were negative (data lanes 8 and 18 and additional data not shown), six of seven SFG -F/ S-EGFP colonies were positive (lane 5) for EGFP DNA ( 86% transduction efficiency ). Nine colonies grown in the presence of 5Â10 17 ) . This result was consistent with the fluorescence microscopy results from experiment 4 (100% of colonies were green fluorescent ). Eight colonies from CFU -GM assay without MTX, generated by week 5 LTC cells without MTX, were also analyzed for vector DNA ( Fig 9) . Four of eight colonies were positive (lanes 3, 5, 6, 7 ). This result was consistent with the relatively lower transduction efficiency in this experiment ( 56% ) as described above.
Discussion
EGFP is a useful marker that can be used to optimize transduction conditions and evaluate the effect of hematopoietic growth factors on stem cell activation and expansion. 18, 29 We have generated a retroviral vector containing a fusion cDNA of EGFP and mutated DHFR. This vector was employed to confer drug resistance and investigate the selection process at the stem cell level in LTC using CAFC analysis. The expression of EGFP from both our control vector and fusion vector was equivalent by FACS analysis and fluorescence microscopy. Fusion vectortransduced NIH3T3 cells conferred MTX resistance comparable to that of our previously published nonfusion vector, SFG -F /S -IRES -Neo, transduced cells. 16 As we hypothesized earlier, 16 we now demonstrate that human primitive hematopoietic cells expressing a mutated DHFR ( F/ S) gene can be selected at the level of CAFC in vitro LTC. Moreover, there was also expression of the second gene (EGFP ) with nearly 100% concordance.
The CD34 + -enriched cells were obtained from cancer patients who had been exposed to variable degrees of chemotherapy prior to stem cell mobilization. The impact of this on the number and quality of stem cells recovered and subsequently transduced is an important variable. The variations in transduction and proliferative capacity illustrated in these investigations provide us with a realistic model of the clinical situation where this form of gene therapy may be useful. In these investigations, CD34 + -enriched cells from four different patient samples were transduced. Each patient had been subjected to heavy, albeit diverse, chemotherapy courses and different mobilization regimens. Despite our application of the same transduction method, we observed a wide range of transduction efficiencies in the four sets of experiments. The lowest transduction efficiency was observed in experiment 2. This low transduction efficiency may have been due to resistance of the stem cells to entry into the cell cycle because the FACS analysis showed that 94% of cells was still CD34
+ after the 5 -day transduction procedure. We cannot rule out possible toxic effects of the virus preparation during the transduction period, but variability within patient samples is a more likely explanation for the different transduction efficiencies. MTX treatment resulted in nearly 100% selection of mature progenitors (CFU -GM, BFU -E) in the suspension cell population throughout the LTC. This finding was supported by the increased incidence of EGFP + cells by the second or third week. The reason for the delay in reaching the maximum of GFP positivity in experiment 2 is probably due to lower number of transduced cells ( only 16% GFP + cells at the initiation of the LTC ).
CAFC assay for these four separate experiments also consistently demonstrated a result similar to the suspension cell data. The absolute number of CAFC was variable in each experiment, which could be due to experimental variation but most likely patient variability. Experiments 1 and 4 with fusion vector -transduced groups showed the maximum relative number of CAFC with MTX exposure compared to the mock -or control vector -transduced group without MTX. This finding is probably related to the higher number of total progenitor cells seeded in the flask for the fusion vector group as well as high transduction efficiency seen with this vector, which resulted in a high number of surviving CAFC following MTX treatment. An interesting observation through all sets of experiments was that some cobblestone areas derived from the fusion protein -transduced cells with no MTX treatment frequently appeared chimeric with both GFP + and GFP À phase dark cells in a cobblestone area instead of totally GFP + cobblestone areas observed in the MTX treatment group (data not shown ). The cobblestone areas are considered to be clonal so that the GFP negativity may be caused by a vector-silencing phenomenon.
All experimental sets demonstrated a decreased total cell count after 3 or 4 weeks of culture except for set 1, which showed a continuous increase in the mock -transduced total cell count after week 5 of LTC. This difference could be due to patient variability and the fact that mock cells were not exposed to the retronectin-coated plates during the transduction period. Possibly, multiple retronectin adhesion steps deplete cells needed to expand cell production long term. This is an observation from a small number of experiments, but it may need to be explored in the future in order to optimize transduction and maintenance of long -term repopulating cells.
Although GFP positivity by fluorescence microscopy was sufficiently sensitive to allow detection of transduced CFU -GM, fluorescence microscopy may underestimate the number of transduced colonies due to silencing or low levels of expression. The correlation between MTX resistance and GFP positivity was demonstrated by the percentage of GFP + cells in CFU -GM assay (nearly 100% GFP positivity, except for experiment set 1 which showed only 62% positivity ) at MTX concentrations of 5Â10 À 8 M where only transduced colonies survived. We noted that the brightness of green fluorescence was enhanced by MTX treatment, especially in the methylcellulose colony assays, which might have increased the efficiency of detection of transduced colonies by fluorescence microscopy.
In summary, we have shown that genetically modified human primitive hematopoietic progenitor cells, demonstrated as week 5 CAFC and week 5 CFU -C, may be selected in LTC by drug treatment. The mutated DHFR and the MTX selection system may overcome low transduction efficiencies of human long -term repopulating stem cells, which has been one of the major hurdles in gene therapy for genetic disorders of the lymphohematopoietic system. In addition, such drug -resistant stem cells may afford significant myeloprotection in cancer patients treated with high -dose MTX treatment.
